
|Videos|June 2, 2015
Adjuvant Chemo in High-Risk Localized Prostate Cancer
Author(s)Howard M. Sandler, MD
This video examines a phase III study that tested the addition of docetaxel and prednisone to standard therapy as adjuvant treatment for men with high-risk localized prostate cancer.
Advertisement
In this video, Howard M. Sandler, MD, of Cedars-Sinai Medical Center in Los Angeles, discusses a phase III study that tested the addition of docetaxel and prednisone to standard therapy as adjuvant treatment for men with high-risk localized prostate cancer.
Dr. Sandler presented results of the trial at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab Yields High pCR Rate in Desmoplastic Melanoma
2
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
3
Reducing Secondary Diagnostic Delay Through the Breast Clinical Reporting and Data System
4
Fecal Microbiota Transplantation Shows Feasibility in Metastatic RCC
5
































